Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Jun 2025 According to a Celldex Therapeutics Inc Media Release, data from this study was presented by Dr. Martin Metz in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025.
14 Jun 2025 Results presented in the Celldex Therapeutics Media Release.
12 Jun 2025 According to a Celldex Therapeutics Inc Media Release, Unprecedented 76 Week Results data from this study being presented in a late breaking oral presentation at the EAACI Congress 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com